SI
RIGL icon

Sofinnova Investments’s Rigel Pharmaceuticals RIGL Stock Holding History

Sofinnova Investments’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-7,130
Closed -$252K – 67
2018
Q1 		$252K Buy
+7,130
New +$285K 0.04% 43

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sofinnova Investments's RIGL Position: Q3 2020 in Review

Sofinnova Investments sold out of Rigel Pharmaceuticals (RIGL) in Q3 2020, closing a stake of 33,970 shares — an estimated $622K sold.

Sofinnova Investments first reported a position in RIGL in Q1 2018 and held it in 6 quarters. The position peaked at $10.5M in Q3 2018. 138 funds tracked by Wall St. Rank hold RIGL as of Q3 2020.

  • Sofinnova Investments reported no remaining Rigel Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Sofinnova Investments sold 33,970 Rigel Pharmaceuticals shares in Q3 2020, an estimated $622K.
  • Sofinnova Investments first reported a position in Rigel Pharmaceuticals in Q1 2018 and held it in 6 quarters.
  • Sofinnova Investments's Rigel Pharmaceuticals position peaked at $10.5M in Q3 2018.
  • 138 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2020.

Based on Sofinnova Investments's 13F filing for Q3 2020, filed 13 Nov 2020.